A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer

Annals of Oncology

Volumn 20, Issue 12, 2009, Pages 1964-1970

  Ychou, Marc ^a   Hohenberger, W ^b   Thezenas, S ^a   Navarro, M ^c   Maurel, J ^d   Bokemeyer, C ^e   Shacham Shmueli, E ^f   Rivera, F ^g   Kwok Keung Choi, C ^h   Santoro, A ⁱ  

^a CENTRE VAL D AURELLE   (France)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^g HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^h QUEEN MARY HOSPITAL   (Hong Kong)

ⁱ HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

5 fluorouracil; Adjuvant treatment; Colorectal cancer; FOLFIRI; Resection of liver metastases

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER ADJUVANT THERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; EPISTAXIS; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; SURVIVAL RATE; UPPER ABDOMINAL PAIN; VOMITING;

EID: 70449105423     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp236     Document Type: Article

References (40)

1. Parkin DM, Bray F, Ferlay J. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Kemeny N, Fata F. Arterial, portal, or systemic chemotherapy for patients with hepatic metastasis of colorectal carcinoma. J Hepatobiliary Pancreat Surg 1999; 6: 39-49.
3. Borner MM. Neoadjuvant chemotherapy for unresectable liver metastases of colorectal cancer - too good to be true? Ann Oncol 1999; 10: 623-626.
4. Rougier P, Milan C, Lazorthes F et al. Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Fondation Francaise de Cancerologie Digestive. Br J Surg 1995; 82: 1397-1400.
5. Thirion P, Michiels S, Pignon JP et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: An updated meta-analysis. J Clin Oncol 2004; 22: 3766-3775.
6. Malafosse R, Penna C, Sa Cunha A. Surgical management of hepatic metastases from colorectal malignancies. Ann Oncol 2001; 12: 887-894.
7. Rees M, John TG. Current status of surgery in colorectal metastases to the liver. Hepatogastroenterology 2001; 48: 341-344.
8. Nordlinger B, Guiguet M, Vaillant JC et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francxaise de Chirurgie. Cancer 1996; 77: 1254-1262.
9. Mamounas E, Wieand S, Wolmark N et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999; 17: 1349-1355.
10. Gill S, Loprinzi CL, Sargent DJ et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004; 22: 1797-1806.
11. Andre T, Quinaux E, Louvet C et al. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: Final results of GERCOR C96.1. J Clin Oncol 2007; 25: 3732-3738.
12. Lygidakis N, Ziras N, Parissis J. Resection versus resection combined with adjuvant pre- and post-operative chemotherapy-immunotherapy for metastatic colorectal liver cancer. A new look at an old problem. Hepatogastroenterology 1995; 42: 155-161.
13. Asahara T, Kikkawa M, Okajima M et al. Studies of postoperative transarterial infusion chemotherapy for liver metastasis of colorectal carcinoma after hepatectomy. Hepatogastroenterology 1998; 45: 805-811.
14. Kemeny N, Huang Y, Cohen AM et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999; 341: 2039-2048.
15. Kemeny MM, Adak S, Gray B et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: Surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy - an intergroup study. J Clin Oncol 2002; 20: 1499-1505.
16. Lorenz M, Muller HH, Schramm H et al. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen). Ann Surg 1998; 228: 756-762.
17. Portier G, Elias D, Bouche O et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006; 24: 4976-4982.
18. Kohne CH, van Cutsem E, Wils J et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005; 23: 4856-4865.
19. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000; 355: 1041-1047.
20. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-914.
21. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004; 22: 229-237.
22. Mackay HJ, Billingsley K, Gallinger S et al. A multicenter phase II study of "adjuvant" irinotecan following resection of colorectal hepatic metastases. Am J Clin Oncol 2005; 28: 547-554.
23. de Gramont A, Bosset JF, Milan C et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 1997; 15: 808-815.
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
25. Parks R, Gonen M, Kemeny N et al. Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: Analysis of data from two continents. J Am Coll Surg 2007; 204: 753-761discussion 761-1753.
26. Figueras J, Torras J, Valls C et al. Surgical resection of colorectal liver metastases in patients with expanded indications: A single-center experience with 501 patients. Dis Colon Rectum 2007; 50: 478-488.
27. Mitry E, Fields A, Bleiberg H et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials. J Clin Oncol 2008; 26: 4906-4911.
28. Sargent DJ, Wieand HS, Haller DG et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2005; 23: 8664-8670.
29. Fong Y, Fortner J, Sun RL et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230: 309-318discussion 318-321.
30. Van Cutsem E, Nordlinger B, Adam R et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 2006; 42: 2212-2221.
31. Nordlinger B, Van Cutsem E, Rougier P et al. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer 2007; 43: 2037-2045.
32. Lazorthes F, Navarro F, Ychou M et al. [Therapeutic management of hepatic metastases from colorectal cancers]. Gastroenterol Clin Biol 2003; 27: Spec No 2: B7.
33. Wang X, Hershman DL, Abrams JA et al. Predictors of survival after hepatic resection among patients with colorectal liver metastasis. Br J Cancer 2007; 97: 1606-1612.
34. Saltz LB, Niedzwiecki D, Hollis D et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: Results of CALGB 89803. J Clin Oncol 2007; 25: 3456-3461.
35. Ychou M, Raoul J, Douillard J et al. A phase III randomized trial of LV5FU2+Irinotecan vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02 FFCD9802). Ann Oncol 2009; 20: 674-680.
36. Nordlinger B, Sorbye H, Glimelius B et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomised controlled trial. Lancet 2008; 371: 1007-1016.
37. Gruenberger B, Tamandl D, Schueller J et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008; 26: 1830-1835.
38. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634.
39. Bokemeyer C, Bondarenko I, Hartmann J et al. KRAS status and efficacy of firstline treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience. J Clin Oncol 2008; 26: 178s.
40. Van Cutsem E, Lang I, D'haens G et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol 2008; 26: 5s.